Skip to content
Screener

Travere Therapeutics, Inc. TVTX Business Segments — External research and development

Similar metrics at other companies

Incyte logo
INCYReportable Segment — Research and development - external
$248.34M+1.1%
Incyte logo
INCYReportable Segment — Research and development - internal
$268.62M+13.5%
Sionna Therapeutics logo
SIONReportable Segment — External research and development expense
$12.93M+29.6%
ImmunityBio, Inc. logo
IBRXReportable Segment — Research and Development Expense, Internal
$47.91M+12.1%
Denali Therapeutics Inc. logo
DNLITherapeutics Segment — External research and development expense
$40.42M+7.5%
Biogen logo
BIIBReportable Segment — Research and development:
$167.1M-0.7%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K—
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept tvtx:ExternalResearchAndDevelopment.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Less:
Cost of goods sold1,9504,679
Research and development:
External research and development27,72822,355
Internal personnel costs24,52520,102
Other research and development4,8414,432
Total research and development57,09446,889
Selling, general and administrative80,25460,413

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s business segments — external research and development?
Travere Therapeutics, Inc. (TVTX) reported business segments — external research and development of $27.73M in Q1 2026.
How has Travere Therapeutics, Inc.'s business segments — external research and development changed year-over-year?
Travere Therapeutics, Inc.'s business segments — external research and development increased by 24.0% year-over-year, from $22.36M to $27.73M.
What is the long-term trend for Travere Therapeutics, Inc.'s business segments — external research and development?
Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — external research and development has grown at a -6.2% compound annual growth rate (CAGR), from $129.7M to $107.04M.
What does business segments — external research and development mean?
This metric tracks expenditures paid to third-party organizations, such as contract research organizations or clinical trial sites, to support the development of the company's drug pipeline. It highlights the company's reliance on external partnerships to advance late-stage clinical programs.

Ask your AI about Travere Therapeutics, Inc.'s business segments — external research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude